AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06523036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined chiropractic care and Tai Chi
Description: Chiropractic will be personalized to the patients clinical needs within the scope of chiropractic practice in the Commonwealth of Massachusetts including: posture correction/spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation/mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports. Chiropractic will be administered by one of two chiropractors at the Osher Clinical Center. Tai Chi will take place at one of two schools used in prior NIH funded trials.
Study NCT00942292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipidem- fish oil emulsion BBraun UK
Study NCT03700814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Description: Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
Study NCT03725007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib is administered as an oral solution or tablet as described in protocol.
Study NCT03410342 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LFV
Description: 1 apple/banana/small bunch of grapes per day plus 1 portion of carrot/pepper/tomato per day
Study NCT03410342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFV
Description: 4 portions of fruits (apples, bananas, grapes, pears) plus 4 portions of vegetables (carrots, cucumber, sweet peppers, tomatoes), of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
Study NCT03410342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC
Description: 4 portions of citrus fruits (clementines, grapefruits, lemons, oranges) plus 4 portions of cruciferous vegetables (broccoli, brussels sprouts, cauliflower, kale, savoy cabbage) per day.
Study NCT03011255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peptide specific CTL
Description: Radiation: RT to 60 Gy, 5 x per week，for 6 weeks Biological: Peptide specific CTL Peptide specific CTL will be administered by intravenous injection on day 28 of radiation.
Study NCT03147794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyndMove
Description: A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
Study NCT01431118 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: specific dragon boating training intervention
Description: male athletes of the german national dragon boat team performing three specific training units at one day
Study NCT01431118 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: specific dragon boat intervention
Description: women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
Study NCT01750424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting
Study NCT01750424 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Subjects in this arm will only be followed up and have no procedure performed.
Study NCT03790839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin (Januvia® 100 mg tablets for oral administration)
Study NCT03790839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Description: Glucokinase activator currently under development
Study NCT03727503 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PPV from the capstesia
Description: we will challenge the application by doing 2 maneuvers: the first one is to increase the PEEP level from 5 to 15 cmH2O and the second one is the infusion of a mini-fluid challenge (100 ml) followed by the other 400 ml.
Study NCT02764905 — intervention group
Intervention type: BEHAVIORAL
Intervention: intensive cognitive physical rehabilitation program
Description: include 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies.
Study NCT01344980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stainless steel suture
Description: Stainless steel suture material will be used (size 3-0) in an MGH repair technique
Study NCT01344980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene suture
Description: Polypropylene suture (size 3-0) will be used in a double-locking loop repair technique
Study NCT01344980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aggressive early active range of motion rehabilitation
Description: Patients undergoing this form of rehabilitation will have their splints discontinued at 4 weeks and ideally will be back at work at normal duties by 6 weeks. This rehabilitation uses more movement at a faster progression than other early active range of motion protocols.
Study NCT01344980 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early active range of motion rehabilitation
Description: Patients undergoing this form of rehabilitation will have their splints discontinued at 6 weeks and ideally will be back at work at normal duties by 10-12 weeks. This rehabilitation uses less movement at a slower progression than the early AROM rehabilitation protocol specified in the experimental group
Study NCT02203799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT)
Description: The peanut protein is ingested in the form of peanut flour. Peanut flour will be given in small pre-measured soufflé cups containing the amount of peanut flour that needs to be eaten for one dose. One dose will be taken per day. Dosage of the peanut flour will begin with 1.8 mg of peanut protein during the initial visit or the lowest tolerated dose on initial challenge and increased every 2 during the build-up phase until the maintenance dose of peanut protein (3900 mg) is reached.
Study NCT02671266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
Study NCT02671266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
Study NCT01881230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
Study NCT00681109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% IL-1Ra
Description: 2.5% custom made topical IL-1Ra three times a day in both eyes for three months
Study NCT00681109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: custom eye drop to be applied three times a day in both eyes for three months
Study NCT00681109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% IL-1Ra
Description: 5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months
Study NCT02504801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
Study NCT00701415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase beta
Description: Powder for concentrate for solution for infusion 1.0 mg/kg/4 weeks
Study NCT00701415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase beta
Description: Powder for concentrate for solution for infusion 0.5 mg/kg/2 weeks
Study NCT02067494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Soft Tissue Release
Description: Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
Study NCT02067494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping treatment
Description: Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain.
Study NCT02261233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Up to 4 sessions of osteopathic manipulative treatment (once per week)
Study NCT01228292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis
Study NCT03316690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Description: Daily treatment with metformin tablets for 101 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2
Study NCT03316690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2
Study NCT03316690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
Study NCT03316690 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical training
Description: Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
Study NCT01824849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total arytenoidectomy
Description: Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis
Study NCT01824849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial arytenoidectomy
Description: Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
Study NCT00807599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant x 1 or x 2
Description: After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.~On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L.
Study NCT00807599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide and dexamethasone
Description: Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
Study NCT01881230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Study NCT01881230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Study NCT01881230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
Study NCT04301752 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MoCA
Description: Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.
Study NCT01868230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Study NCT01228292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrasate
Description: Citrasate is infused as a dialysate
Study NCT04454541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided nerve block for headache management
Description: The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.
Study NCT04454541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve block for headache management
Description: The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.
Study NCT02604758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Psychiatric Nursing Approach Based On The Tidal Model
Description: To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
Study NCT04326686 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intervention: nuts and wholegrains with dietary advice for a blood-pressure lowering diet
Description: 30g mixed unsalted tree nuts (almonds, hazelnuts and almonds) per day; 3 portions of wholegrain foods per day (including wholegrain cereal products, wholegrain bread and wholegrain pasta); guidance for following the Dietary Approaches to Stop Hypertension (DASH) diet
Study NCT01571869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit
Description: 1-Intervention with test product (morning, evening or snack)
Study NCT01571869 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2- Low fat drinkable fermented dairy product without plant sterols (control)
Description: 2 - Intervention with control product (morning and/or evening)
Study NCT02483390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychosocial intervention
Description: e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
Study NCT00918554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
Study NCT00918554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
Study NCT01818440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D Roadmap software
Description: Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
Study NCT01818440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Description: Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
Study NCT01594606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention
Description: The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
Study NCT01459913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet
Study NCT01594606 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal-assisted intervention
Description: The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
Study NCT00952003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel
Study NCT01061580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harvest SmartPReP2 BMAC System
Description: Injection of 10, 15, or 20 cc of BMAC
Study NCT02417350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks
Study NCT02417350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.
Study NCT00291941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Henogen HBV vaccine
Description: 20µg, Month 0, 2 and 6
Study NCT00291941 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FENDRIX
Description: 20 µg,Months 0, 1, 2 and 6
Study NCT03795532 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Shock wave lithotripsy
Study NCT04150809 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study NCT01379885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique
Description: Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
Study NCT01379885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent participation technique
Description: The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
Study NCT01106885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Care Management (MCM)
Description: * Basic physical activity counseling~* Notify PCP and facilitate initiation of antidepressants~* Medication monitoring calls at 1, 2, 4, 6, 8, 10, and 12 weeks\*~* 1/mo monitoring in continuation phase (mos. 4-12)\*~* Report \& recommendations to PCP after each patient call~* Note: \*average of 10 minutes of telephone time each (series is repeated if second antidepressant trial is needed)
Study NCT01881230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.